<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Apollo Endosurgery, Inc. ("Apollo") APEN, a leader in less 
 invasive medical devices for bariatric and gastrointestinal procedures, 
 today announced its participation during Digestive Disease Week 2017. 
 DDW will be held May 6-9, 2017 at McCormick Place in Chicago, Illinois.
 
 
 Over 35 clinical abstracts will be presented on Apollo's endo-bariatric 
 products which include the OverStitch™ Endoscopic Suturing System and 
 the ORBERA® Intragastric Balloon. These clinical abstracts will include 
 statistical proof points supporting methods to improve the efficiency 
 and effectiveness of both products, as well as research into possible 
 future indications.
 
 
 During the conference, DDW will host several hands-on workshops 
 including sessions that feature ORBERA® and OverStitch™ technologies. In 
 addition, the Apollo Mobile Learning Center will be in Chicago to 
 support hands-on physician training. The Apollo Mobile Learning Center 
 is a state-of-the-art mobile training facility that allows for advanced 
 endoscopic training programs to be conducted locally. These sessions 
 further Apollo's mission to develop safe, effective, innovative and 
 less-invasive solutions for bariatric and gastrointestinal therapies.
 
 
 To learn more about ORBERA® and OverStitch™, please visit Apollo 
 Endosurgery at booth #2204 during the conference.
 
 
 About ORBERA®
 
 
 ORBERA® is an incision-less, non-surgical weight loss solution designed 
 for adult patients suffering from obesity, who are not appropriate for 
 or considering invasive surgery, but for whom diet and exercise or 
 pharmaceutical interventions have not worked.
 
 
 In a non-surgical (endoscopic) procedure, the thin and deflated ORBERA® 
 balloon is placed into the stomach. It is then filled with saline until 
 it's about the size of a grapefruit. The procedure typically takes about 
 20 to 30 minutes and the patient can generally go home the same day. At 
 six months, through another non-surgical, the ORBERA® balloon is 
 deflated and then removed.
 
 
 Once the balloon is in place, the patient receives an individually 
 tailored support program through the ORBERA® Managed Weight Loss System 
 team of experts to help keep them motivated, coordinate their program 
 and help them work through weight loss barriers to meet their long-term 
 weight loss goals. Coaching takes place over 12 months, even though the 
 balloon is removed after six months. The program is designed to help the 
 patient develop sustainable, healthy habits that will help keep weight 
 off over time.
 
 
 For more than 20 years, the global medical community has been using 
 intragastric balloons from the makers of ORBERA® to help thousands of 
 people lose weight. More than 220,000 ORBERA® balloons have been 
 distributed worldwide in over 80 countries.
 
 
 For additional information regarding ORBERA®, please visit 
 orbera.com.
 
 
 For full safety information please visit orbera.com/dfu, talk with your 
 doctor, or call Apollo Customer Support at 1-855-MYORBERA.
 
 
 About OverStitch™
 
 
 The OverStitch™ endoscopic suturing system enables advanced endoscopic 
 surgery by allowing physicians to place full-thickness sutures from a 
 flexible endoscope. This new technology enables a secure approximation 
 of tissue endoscopically and a wide range of less invasive solutions for 
 physicians who treat defects in both the upper and lower GI tract of 
 their patients. Additionally, physicians are leveraging endoscopic 
 suturing to perform a variety of advanced bariatric procedures. For more 
 information regarding OverStitch™ go to: apolloendo.com.
 
 
 About Apollo Endosurgery, Inc.
 
 
 Apollo Endosurgery, Inc. is a medical device company focused on less 
 invasive therapies for the treatment of obesity, a condition facing over 
 600 million people globally, as well as other gastrointestinal 
 disorders. Apollo's device based therapies are an alternative to 
 invasive surgical procedures, thus lowering complication rates and 
 reducing total healthcare costs. Apollo&#39;s products are offered in over 
 80 countries today.
 
 
 Apollo's common stock is traded on NASDAQ Global Market under the symbol 
 &#34;APEN.&#34; For more information regarding Apollo Endosurgery, go to: 
 apolloendo.com.
 
 
 © 2017 Apollo Endosurgery, Inc. All rights reserved. Any third-party 
 trademarks used herein are the property of their respective owners.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170502006894r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170502006894/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170502006894/en/</a></body></html>

Press Releases

Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2017 Conference (DDW) 

APEN

Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2017 Conference (DDW)


Prof. Sir Brian J. Hoskins and Prof. John Michael Wallace in the Field of Resources, Energy, the Environment, and Social Infrastructure


Prof. Ronald M. Evans in the Field of Medical Science and Pharmaceutical

The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance


Global leading IT firm FPT today announced a comprehensive strategic partnership with NVIDIA, aiming to offer a one-stop shop for AI &amp; Cloud consisting of AI products, GPU infrastructure, tech experts, and domain

FPT to Shape the Future of AI and Cloud on a Global Scale in Collaboration with NVIDIA


In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the

Regula Pinpoints Top Three Business Challenges with Verification of International Customers


Edge Impulse, the leading platform for building, refining and deploying machine learning models to edge devices, has unveiled a novel technology for unlocking visual anomaly detection on any edge device, from NVIDIA

Edge Impulse Brings Industrial Computer Vision Breakthroughs in Anomaly Detection to Any Edge Device for the First Time


LatticeFlow AI, the leading AI platform for building safe and trustworthy AI solutions, proudly joins the U.S. AI Safety Institute Consortium (AISIC). Following a series of strategic engagements with U.S. government

LatticeFlow AI Joins the U.S. AI Safety Institute Consortium

FFIE


Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) (&#34;Faraday Future&#34;, &#34;FF&#34; or &#34;Company&#34;), a California-based global shared intelligent electric mobility ecosystem company, announced that consultant Werner Wilhelm is